Aemetis (NASDAQ:AMTX) Given New $3.00 Price Target at UBS Group

Aemetis (NASDAQ:AMTX - Get Free Report) had its price objective lifted by investment analysts at UBS Group from $2.20 to $3.00 in a research report issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the specialty chemicals company's stock. UBS Group's price target would suggest a potential upside of 21.21% from the stock's previous close.

A number of other research analysts also recently commented on AMTX. HC Wainwright reaffirmed a "buy" rating and issued a $28.00 price target on shares of Aemetis in a research note on Friday, March 14th. Ascendiant Capital Markets upped their price target on shares of Aemetis from $19.00 to $20.00 and gave the stock a "buy" rating in a report on Friday, June 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $13.63.

Aemetis Price Performance

Aemetis stock traded up $0.13 during mid-day trading on Monday, hitting $2.48. 940,255 shares of the company's stock traded hands, compared to its average volume of 783,193. The stock has a market cap of $137.04 million, a price-to-earnings ratio of -1.32 and a beta of 1.48. The firm has a 50 day simple moving average of $1.72 and a two-hundred day simple moving average of $2.00. Aemetis has a fifty-two week low of $1.22 and a fifty-two week high of $4.73.

Aemetis (NASDAQ:AMTX - Get Free Report) last announced its earnings results on Thursday, May 8th. The specialty chemicals company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.08). The firm had revenue of $42.89 million during the quarter, compared to the consensus estimate of $59.35 million. During the same quarter in the prior year, the business posted ($0.58) EPS. On average, research analysts anticipate that Aemetis will post -2.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in Aemetis by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 934,993 shares of the specialty chemicals company's stock worth $2,516,000 after purchasing an additional 10,700 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Aemetis by 1,130.0% during the fourth quarter. Jane Street Group LLC now owns 374,016 shares of the specialty chemicals company's stock worth $1,006,000 after buying an additional 343,609 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Aemetis by 3.7% during the fourth quarter. Northern Trust Corp now owns 297,023 shares of the specialty chemicals company's stock worth $799,000 after buying an additional 10,658 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Aemetis by 71.9% in the first quarter. Goldman Sachs Group Inc. now owns 218,404 shares of the specialty chemicals company's stock valued at $380,000 after purchasing an additional 91,367 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Aemetis by 515.9% in the 4th quarter. JPMorgan Chase & Co. now owns 120,716 shares of the specialty chemicals company's stock valued at $325,000 after buying an additional 101,116 shares during the last quarter. Institutional investors own 27.02% of the company's stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.